GZR102 vs HR17031
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor / GLP-1 receptor (combination) · full Type 2 Diabetes pipeline
GZR102
Developed by Gan & Lee Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
HR17031
Developed by Jiangsu Hengrui Pharmaceuticals
NCT06881264 · Phase 3 · completed
The randomized Phase 3 trial enrolled 401 adults with type 2 diabetes uncontrolled on oral drugs, with HbA1c change at week 26 as the primary endpoint against insulin glargine. The sponsor reports that HR17031 was superior (-1.85% vs -1.06%); the registry has no posted results.
Caveat: this result is taken from a company announcement, not from the trial registry or a peer-reviewed publication. Treat it as the sponsor's own statement.
Reported efficacy
Change in HbA1c: Changes in HbA1c from baseline to week 26: Week 26 HbA1c change, LS mean: HR17031 -1.85% vs insulin glargine -1.06% (sponsor-reported) (met)
Result source: NCT06881264
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | GZR102 | HR17031 |
|---|---|---|
| HbA1c, change | —Not reported | —Not posted · NCT06871761 |
| Body weight, change (kg) | —Not reported | —Not posted · NCT06871761 |
| HbA1c below 7% | —Not reported | —Not posted · NCT06871761 |
| Fasting plasma glucose, change | —Not reported | —Not posted · NCT06871761 |
| 3-point MACE (% with event) | —Not reported | —Not posted · NCT06871761 |
HbA1c, change
- GZR102
- —Not reported
- HR17031
- —Not posted · NCT06871761
Body weight, change (kg)
- GZR102
- —Not reported
- HR17031
- —Not posted · NCT06871761
HbA1c below 7%
- GZR102
- —Not reported
- HR17031
- —Not posted · NCT06871761
Fasting plasma glucose, change
- GZR102
- —Not reported
- HR17031
- —Not posted · NCT06871761
3-point MACE (% with event)
- GZR102
- —Not reported
- HR17031
- —Not posted · NCT06871761
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
GZR102: no structured comparison results are available for Type 2 Diabetes.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GZR102's landscape · HR17031's landscape